Introduction
============

Overactive bladder syndrome (OAB) and interstitial cystitis/painful bladder syndrome (IC/PBS) are common, chronic, pelvic disorders affecting approximately ∼16% of the western population ([@B68]; [@B81]; [@B114]; [@B156]). Urgency, frequency, and nocturia are common symptoms of both OAB and IC. However, these conditions may be differentiated by the presence of urge urinary incontinence in patients with OAB and pelvic pain in IC patients ([@B109]; [@B67]; [@B72]; [@B77]). As both of these disorders are diagnosed in the absence of bacterial infection or obvious pathology, the etiology of OAB and IC/PBS symptoms remain unknown. Accordingly, efficacious therapeutic options are limited, contributing to the significant societal and economic impact of greater than \$70 billion per annum in the United States ([@B131]; [@B41]).

Normal bladder function requires coordination of afferent signals originating from the bladder wall with excitatory and inhibitory signals from the anterior cingulate cortex (ACC), insula, and hypothalamus to provide an overview of the appropriateness to urinate that is ultimately under conscious control by the prefrontal cortex (Figure [1](#F1){ref-type="fig"}; [@B61]; [@B107]). Bladder afferents embedded within the detrusor smooth muscle show exquisite sensitivity for mechanical distension but are also found innervating the urothelium ([@B175], [@B176], [@B174]; [@B149]). This topology provides a secondary level of resolution to the transmission of sensory stimuli, including the detection of bladder infection, urothelial inflammation, or barrier breakdown (Figure [1](#F1){ref-type="fig"}). Accordingly, bladder sensory afferents express a range of anti- and pro-nociceptive receptors and ion channels ([@B46]; [@B64]) that integrate the input from this complex signaling environment and can induce a range of sensations from fullness through to pain ([@B50]). These afferents, whose cell bodies are located within the dorsal root ganglia (DRG), project via the pelvic, hypogastric/splanchnic nerves, synapse within the dorsal horn of the lumbosacral (LS, L5-S1) and thoracolumbar (TL, T10-L2) spinal cord (Figure [1](#F1){ref-type="fig"}; [@B50]; [@B33]) and terminate within the periaqueductal gray (PAG) ([@B50]). The PAG acts as an integration center for afferent signals from the spinal cord and higher brain centers ([@B61]). A conscious "urge" to urinate is perceived when afferent activity increases beyond a pre-set threshold and, if modulating input from the brain permits, the PAG activates the pontine micturition centre (PMC) to induce efficient voiding ([@B7]; [@B50]; [@B61]; [@B107]).

![Spinal innervation of the bladder. The afferent nerves innervating the bladder wall extend into the detrusor smooth muscle to detect bladder stretch, and into the bladder urothelium to detect bladder stretch, infection, inflammation, and barrier breakdown. The bladder lumen contains numerous commensal bacteria as well as toxic contents such as urea and high potassium. Bacterial infection of the urothelium induces apoptosis of urothelial cells, the release of cytokines, and the infiltration and activation of the immune response, including mast cell degranulation and the subsequent release of histamine and cytokines that can sensitize bladder afferent neurons. During bladder stretch the urothelium releases an array of neurotransmitters, including ATP, which can activate bladder afferents. Breakdown of the urothelial barrier allows access of toxic urine contents into the underlying bladder interstitium which can activate and sensitize bladder afferents. Bladder afferents project via the pelvic nerve or the splanchnic nerve to the dorsal horn of the thoracolumbar and lumbosacral spinal cord, where they activate second order neurons within the spinal cord synapse in the thalamus or the PAG of the midbrain. Thalamic projections provide input into limbic and cortical structures to provide the emotional affective and conscious component of the voiding reflex pathway. The thalamus relays to the PAG and the PAG feeds into the PMC to signal micturition. TL, Thoracolumbar; LS, lumbosacral; SC, spinal cord; PFC, Prefrontal Cortex; ACc, Anterior cingulate cortex; Hyp, hypothalamus; HGN, hypogastric nerve; PAG, periaqueductal gray; PMC, primary micturition center; DRG, dorsal root ganglion; DH, Dorsal horn; Agd, amygdala; LSN, lumbar splanchnic nerve; SPN, pelvic nerve; IMG, inferior mesenteric ganglion; PP, Pelvic Plexus. Figure modified from [@B64].](fnins-12-00931-g001){#F1}

Clinical studies reveal that patients with OAB and IC/PBS perceive sensations of bladder fullness, urge to void, and pain at lower cystometric volumes than healthy subjects ([@B158]; [@B92]; [@B126]). These observations thereby implicate the sensitisation of bladder afferent pathways to physiological stimuli as a key component in the mechanisms underlying these disorders ([@B170]; [@B172]; [@B33]). Furthermore, co-morbidity of depression and anxiety is significantly higher in patients with OAB and IC/PBS, while high psychological stress levels is strongly correlated to exacerbated bladder symptoms ([@B58]; [@B93]; [@B57]; [@B102]; [@B113]). As such, increased intensity of the afferent signal or modulation of the emotional affective state can have profound effects on bladder sensation. A key concept therefore, in the development of OAB and IC/PBS, is chronic sensitisation of the neuronal networks regulating bladder sensation, incorporating structural, synaptic, or intrinsic changes of peripheral or central structures that may drive subsequent changes in downstream sensory pathways ([@B16]; [@B64]).

In this review, for brevity, we summarize both preclinical and clinical research to highlight how alterations in peripheral afferent excitability contribute to the symptoms of OAB and IC/PBS to provide insights into the mechanisms that are hypothesized to mediate these distinct disorders which have many overlapping symptoms. For an excellent review on the potential changes in central processes occurring in OAB see [@B137].

Urothelial Permeability
=======================

Toxic waste metabolites excreted in urine are prevented from accessing the bladder interstitium and embedded afferent endings by a tight urothelial barrier ([@B149]; Figure [1](#F1){ref-type="fig"}). The urothelial barrier is maintained by tight junctions between apical urothelial cells, hydrophobic uroplakin plaques, and a considerable glycosaminoglycan (GAG) mucus layer, that block the movement of small molecules and urine ([@B13]; [@B80]). From a clinical point of view, numerous studies have identified that patients with IC/PBS, but not OAB, have a diminished or damaged urothelium ([@B44]; [@B155]; [@B95]; [@B88]; [@B80]), as well as reduced expression of the tight junction proteins zona occludens 1 (ZO-1) and E-cadherin ([@B105]). Increased bladder permeability due to reduced urothelial integrity is thought to underlie the sensitivity of IC/PBS patients (75%) to the potassium sensitivity test (PST) compared to control patients (4%) ([@B127]). A number of clinical studies also show that OAB patients respond to the PST, however, this may be due to overlap and misdiagnosis between IC/PBS and OAB ([@B119]; [@B109]; [@B25]). Despite these observations, it remains to be determined if bladder permeability is part of the underlying pathology of bladder hypersensitivity in IC/PBS patients or a downstream consequence of localized inflammation that further exacerbates the condition.

Glycosaminoglycan replacement therapy with pentosane polysulfate (PPS) has been shown to improve the symptoms for some, but not all, IC/PBS patients ([@B122]; [@B95]; [@B124]; [@B80]). However, PPS also induces broad anti-inflammatory actions, including the inhibition of mast cell histamine release in the bladder ([@B21]; [@B5]; [@B168]; [@B139]). In addition, pre-clinical studies inducing urothelial permeability with protamine sulfate identified a relatively rapid recovery of the urothelial barrier and structure ([@B97]; [@B59]), via injury-induced proliferation of basal urothelial and stromal cells ([@B145]). A more likely scenario therefore is that bladder permeability in IC/PBS patients is secondary to localized inflammation. Continuous access of toxic urine contents combined with inflammatory mediators, such as cytokines, histamine, and proteases, can sensitize peripheral afferent endings and have the potential to trigger long term changes in neuronal function and neuroplasticity within the entire afferent network ([@B16]; [@B64]).

Altered Release of Urothelial Factors
-------------------------------------

In addition to its role as a physical barrier, the urothelium provides bi-directional communication with underlying primary afferents ([@B98]; [@B13]; [@B116]) via the detection and/or release of a range of excitatory and inhibitory neurotransmitters and neuromodulators including ATP, acetylcholine, nitric oxide (NO), NGF, prostaglandin E2 (PGE2), neurokinin A, and inflammatory mediators as described above (and extensively reviewed by Birder et al.) ([@B47],[@B48]; [@B13]; [@B33]; [@B62]). Altered urothelial mediator release has been identified from OAB and IC/PBS patients in a number of studies and may be a compounding mechanism in the development of chronic neuronal hypersensitivity ([@B90], [@B91]; [@B152]; [@B150]).

Chronic bladder inflammation enhances ATP release from the urothelium and augments purinergic signaling of bladder afferents in rats ([@B147]), whilst both stretch-mediated ATP release and its receptor P2X~3~ are increased in the urothelium of OAB and IC/PBS patients ([@B151], [@B152]; [@B26]; [@B85]). Pre-clinically, acetylcholine, acting via muscarinic receptors also triggers release of ATP, as well as NO and prostanoids from urothelial cells ([@B166]; [@B118]). In animal studies, experimentally induced cystitis upregulates muscarinic receptors and acetylcholine release, as well as subsequent cholinergic regulated urothelial NO release ([@B54]; [@B55]; [@B6]; [@B112]). Notably, PGE2 levels are significantly increased in OAB patients ([@B90], [@B91]), whilst NO and PGE2 levels and receptor expression are also altered in IC/PBS patients with Hunner's legions ([@B161]; [@B84]). Bradykinin stimulates urothelial NGF release and enhances stretch-induced ATP release in a human urothelial cell line ([@B123]; [@B166]), whilst bradykinin 1 (B1) receptor expression is upregulated in human IC/PBS patient bladder samples ([@B10]) and in the urothelium of a rat CYP-induced cystitis model ([@B22]).

Limited causations have been determined for altered urothelial neurotransmitter release or receptor expression in OAB and IC/PBS, but there is accumulating evidence that they are a downstream consequence of inflammation, infection or urothelial breakdown.

Inflammation
============

By definition, the presence of bladder inflammation precludes the clinical diagnosis of OAB. Only a small population of IC/PBS patients exhibit significant inflammation, which is characterized by the presence of Hunner's ulcers ([@B101]). However, it is widely reported that there are increases in the amount of pro-inflammatory mediators within the bladder and urine of both OAB and IC/PBS patients ([@B86]; [@B45]; [@B70]; [@B83]; [@B105]; [@B85]; [@B53]). These pro-inflammatory mediators including histamine, nerve growth factor (NGF), and those released from mast cells, are known to directly sensitize afferent nerve terminals ([@B31]). Furthermore, overexpression of pro-inflammatory genes, oedema, tissue granulation and an increase in macrophages, chemokines, cytokines, eosinophils, as well as T and B cell markers have also been identified in IC/PBS patients ([@B70]; [@B2]). As the majority of cystitis-induced inflammation is localized to the superficial mucosa, urothelial afferents are ideally placed to detect and respond to these environmental changes.

Inflammation-induced sensitisation of afferents is an essential mechanism for the induction of normal wound healing, however, chronic sensitisation of afferents can occur during prolonged inflammation or following a severe bout of inflammation ([@B16]; [@B3]). In support of an inflammatory-mediated pathophysiology in urological disorders, animal models of cystitis have employed a range of chemicals, including acetic acid, acrolein, cyclophosphamide (CYP), zymosan and lipopolysaccharide, that induce both acute and longer lasting bladder hyperactivity ([@B153]; [@B106]; [@B1]; [@B78]). Whilst there are many limitations to the use of inflammatory animal models in the study of symptom defined disorders such as OAB and IC/PBS (comprehensively discussed by [@B51]), these animals show an overactive bladder phenotype, with altered cystometry and enhanced visceromotor response during bladder distension, replicating the reduced bladder capacity, plus the allodynia and hyperalgesia to bladder distension observed in humans ([@B51]; [@B94]; [@B38], [@B37]). Furthermore, bladder afferents show direct sensitisation to chemical and inflammatory stimuli ([@B32]), whilst retrogradely traced bladder-innervating DRG neurons from CYP-treated rats or a naturally occurring feline interstitial cystitis model exhibit lower activation thresholds and sensitisation to current injection ([@B30]; [@B18]). The efficacy of intraluminal therapies to treat OAB and IC/PBS ([@B28]; [@B111]), that either (1) block bladder afferent firing (such as lidocaine and neosaxitoxin) or (2) cause peripheral nerve desensitization (with agents such as resiniferatoxin; RTX), highlight the important role of peripheral afferents in mediating bladder hypersensitivity to distension ([@B9]).

The transient receptor potential (TRP) channel TRPV1 is upregulated in the bladders of patients with OAB and IC/PBS ([@B104]), whilst both TRPV1 and TRPA1 have consistently been implicated in mediating normal and cystitis-induced mechanical sensitivity in rodents by modulating neuronal activation thresholds and enhancing bladder afferent responses to P2X receptor activation ([@B29]; [@B164]; [@B38], [@B37]; [@B173]; [@B63]). A host of additional receptors and channels associated with nociception have also been identified upon bladder afferents that regulate neuronal sensitivity and neuronal excitability in animal models of cystitis, including voltage gated sodium (Na~V~) channels ([@B46]; [@B65]), potassium channels (K~V~) ([@B71]), P2X receptors ([@B30]; [@B20]), TRPV4 ([@B115]) and cannabinoid receptors ([@B73]; [@B82]; [@B11]; [@B74]; [@B120]).

It is possible that a population of patients present without active inflammation or increased bladder permeability but are in fact in remission from a preceding bladder infection or inflammation. Such a scenario could induce a protracted hypersensitive state and correspond to their enhanced sensory symptoms. Indeed, women with a clinical history of recurrent UTI as children are significantly more likely to have a diagnosis of IC/PBS as adults ([@B130]), and preclinical investigations of neonatal bladder insult in rats suggests this may be due to long term sensitisation of sensory pathways ([@B135]; [@B34]; [@B121]). Neuroplasticity of peripheral afferent circuitry following the resolution of inflammation or recovery from tissue injury has been well documented in both somatic and visceral pain models through the induction of neurogenic inflammation and neuronal sprouting ([@B32]; [@B60]; [@B16]). Neonatal bladder inflammation in rats results in hypersensitive responses to inflammatory stimuli as an adult, inducing an overactive bladder phenotype ([@B135]; [@B34], [@B35]), as well as enhanced spontaneous and urinary bladder distension-evoked activity of spinal visceral nociceptive neurons ([@B121]). Alterations in spinal cord circuits responsible for bladder sensation may regulate this phenomenon, as neonatal inflammation induces a downregulation of GABA (Aα-1) receptor microRNA and altered opioid peptide content in the dorsal horn ([@B142]; [@B144]). Furthermore, neonatal zymosan enhances bladder neuropeptide content of CGRP and Substance P compared to sham controls ([@B35]; [@B143]).

Similarly, in pre-clinical models of adult cystitis, bladder overactivity is associated with increases in tyrosine receptor kinase (Trk) A, Trk B, and calcitonin gene-related peptide (CGRP) ([@B160]; [@B134]), which in turn promote inflammation in the tissue where the afferent terminals reside ([@B138]). Furthermore, patients with IC/PBS have higher elevated serum and urinary NGF levels than healthy controls ([@B19]). NGF overexpression in mouse urothelium leads to neuronal hyper-innervation, increased mast cell counts and changes in bladder function ([@B140]). These discoveries may explain the increased sprouting of neuronal terminals identified in the bladders of IC/PBS patients ([@B24]; [@B108]), that has been replicated in rodent models of inflammation *in vivo* and *in vitro* ([@B40]; [@B140]; [@B15]; [@B43]).

Microbiome/Chronic Urinary Tract Infection
==========================================

Following the recent identification of a bladder-specific microbiome, and the role of the gut microbiome in chronic functional gastrointestinal diseases ([@B79]; [@B69]), a link between the balance of bacteria in the bladder and the symptoms of OAB and IC/PBS has been postulated and explored ([@B26]; [@B8]; [@B39]). Moreover, the traditional colony forming unit thresholds for confirming urinary tract infection (UTI) in clinical practice have been questioned, and a role for chronic UTI in the pathogenesis of OAB has been investigated ([@B12]).

Patients with OAB may have genuine uropathogenic infections, and are therefore misdiagnosed, as large numbers of bacteria are undetected by routine mid-stream urine cultures ([@B89]). Indeed, a significantly greater number of patients with refractory idiopathic detrusor overactivity show low count bacteriuria vs. controls ([@B162]). Undiagnosed intracellular bacterial colonization of urothelial cells may also occur in OAB ([@B141]), as OAB patients exhibit significantly greater infected urothelial cell counts and microscopic pyuria than healthy subjects, which also correlates to urgency symptoms ([@B56]). Uropathic *E. coli* infection initiates the release of multiple mediators from the urothelium, including cytokines and interleukins, as well as promoting urothelial barrier defects ([@B167]), which alert the immune system to impending damage and initiate an immune response ([@B3]). Immune cell infiltration and the release of pro-inflammatory cytokines are known to sensitize peripheral afferents ([@B136]), and in this way enhance bladder sensation. In support of these considerations, a recent pilot study revealed that combination antibiotic treatment of both Gram-negative and Gram-positive bacteria significantly improved OAB symptoms as well as the perception of their bladder condition ([@B159]). Furthermore, shifts in the bacterial species that constitute the bladder microbiome have been associated with both the presence and severity of OAB and IC/PBS ([@B146]; [@B165]; [@B26]; [@B96]; [@B27]). For example, women with IC/PBS, but not OAB, have a less diverse microbiota than those without ([@B76]; [@B128]; [@B2]; [@B27]). Interestingly, despite significant inter-patient variability in bladder microbiome, a decrease in *Lactobacillus*, which has antimicrobial properties, in both OAB and IC/PBS patients compared to controls is a common finding ([@B76]; [@B128]; [@B27]). Furthermore, the absence of *Lactobacillus acidophilus* correlates with higher pain scores and higher scores on the interstitial cystitis symptom index ([@B2]). *Proteus*, the urinary pathogen, is also identified more commonly in patients with OAB and lower urinary tract symptoms than healthy controls ([@B89]; [@B27]). These data support a line of communication between the urinary microenvironment and underlying afferent nerves that is likely mediated by the urothelium.

Cross-Organ Sensitisation
-------------------------

Considerable clinical evidence suggests that diseases of the colon, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), can induce subsequent development of pathology in an otherwise unaffected adjacent organ, such as the bladder ([@B65]).

A mouse model of colitis induced by intra-rectal instillation of 2,4,6-trinitrobenzene sulfonic acid (TNBS) induces hyper-excitability of the entire peripheral sensory pathway, from the afferent ending in the colon to the spinal cord ([@B16]). Importantly, TNBS colitis also prompts consistent changes in bladder voiding parameters that replicate the clinical symptoms of urgency and frequency, as well as increased bladder-afferent sensitivity to bladder distention ([@B17]; [@B157]; [@B59]; [@B171]). These symptoms occur in the absence of any overt inflammation or histological damage to the bladder, highlighting the importance of altered afferent sensitivity in maintaining OAB and IC/PBS symptomology ([@B171]).

This "cross-organ sensitisation" is considered to originate within the physiological co-ordination of these pelvic organs, and persistent pathological plasticity of their shared sensory pathways within the thoracolumbar and lumbosacral DRG and spinal cord ([@B129]; [@B65]). Approximately 15% of colonic innervating TL and LS DRG neurons exhibit dichotomising afferents, simultaneously innervating the bladder ([@B23]; [@B171]), whilst a similar proportion of spinal dorsal horn neurons also respond to both urinary bladder and colonic distension ([@B65]). As such, sensitisation of colonic afferent pathways has the potential to directly influence the excitability of bladder afferent pathways. Indeed, a very recent pre-clinical study also indicates that chronic sensitisation of colonic afferent pathways results in the subsequent sensitisation of bladder afferent pathways and the triggering of uncontrolled urinary voiding in mice. Intriguingly, these changes in bladder function can be reversed by a therapeutic treatment targeted only to the colon ([@B66]).

Additionally, neurochemical changes occur within colonic afferent pathways following colitis that indicate the development of neurogenic inflammation ([@B65]). Multiple studies have shown that this translates to persistent upregulation of the neuromodulators NGF, BDNF, CGRP, and the high affinity receptor TrkB in bladder, bladder-innervating DRG neurons, and spinal cord ([@B103]; [@B133]; [@B125]; [@B169]; [@B87]). These receptors and neuropeptides share an intimate relationship enabling the positive feedback of each other ([@B110]; [@B23]; [@B100]; [@B171]), consequently inducing neuronal sensitisation and neurite outgrowth, and likely contributing to cross-organ sensitisation through paracrine actions within the ganglia to increase bladder afferent excitability ([@B169]; [@B148]).

Cortical Regulation: Stress, Anxiety, and Depression
----------------------------------------------------

The sensory signals from bladder afferent converge in the PAG where they are modulated by input from the limbic system (amygdala, hypothalamus, thalamus, cingulate gyrus), insula, and prefrontal cortex ([@B50]), which can in turn modulate or be modulated by the hypothalamic pituitary adrenal (HPA) axis. As such, changes to cortical networks or modulation of the emotional affective state can have profound effects on bladder sensation and may be an underlying mechanism in the development and persistence of OAB and IC/PBS symptoms.

Patients with OAB and IC/PBS report psychological stress levels that are significantly higher than healthy controls ([@B93]), which may be a consequence of HPA axis dysregulation following chronic early life stress (ELS) ([@B154]). Exposure of children to ELS is a significant risk factor for developing HPA abnormalities ([@B4]; [@B131]), and shows strong correlations with the development of depression and anxiety in later life ([@B42]; [@B75]). To this end, a number of studies report higher incidences of ELS and trauma in IC/PBS patients than healthy controls ([@B52]), whilst clinical studies have demonstrated a strong correlation between stress, anxiety, depression, and the symptoms of bladder overactivity in patients with OAB and IC/PBS ([@B58]; [@B57]; [@B102]). The increased prevalence of depression and anxiety in patients with IC/PBS occurs both following and prior to bladder symptoms, indicating a reciprocity in cause and effect, with no clear way to delineate patient cohorts to provide increased mechanistic understanding ([@B113]). In addition to relationships with cognitive disorders, structural abnormalities within the white matter of the brain in women with IC/PBS, which facilitates the communication between and within brain regions, correlates closely to symptom severity ([@B49]). It remains unclear whether these white matter properties are causes or consequences of IC/PBS. It is possible that certain white matter architecture may reflect a predisposition to develop disease, but it is equally plausible that these changes are a consequence of IC/PBS disease progression and future longitudinal studies are required to test this hypothesis.

The link between stress and bladder disorders is supported by pre-clinical studies in rodents that consistently induce bladder overactivity or mechanical hyperalgesia following stress-treatments ([@B14]; [@B117]; [@B36]; [@B99]; [@B163]). In addition, this hypersensitivity has been found to be dependent on ([@B36]), or correlate with, significant changes in brain regions associated with emotional processing and bladder control ([@B163]). Neonatal maternal separation in female mice, as a model of ELS, enhances visceromotor responses to urinary bladder distension accompanied by altered hippocampal input onto the HPA axis ([@B132]). If sensitisation of peripheral afferent endings occurs in these models as a consequence of stress, or if sensitisation is arbitrated solely within the CNS has yet to be fully determined.

Conclusion
==========

This review highlights the complex nature of both OAB and IC/PBS, incorporating evidence for changes in the dynamic signaling environment between the bladder lumen, urothelium, and afferent nerves, coordinating with adaptations to the HPA axis, and emotional affective components of sensory processing mediated within the limbic system. The bladder microbiome, bacterial infection, inflammation, and urothelial permeability contribute to the development of peripheral afferent hyperexcitability that is fundamental to the development of frequency and urgency in OAB, and pain in IC/PBS. In addition, the higher psychological stress levels, increased prevalence of anxiety and depression, as well as clinical co-morbidities with other visceral pain disorders suggests pathological plasticity within the CNS is an important component in the mechanisms underlying both OAB and IC/PBS. Determining the underlying mechanisms of bladder hypersensitivity is paramount to providing novel targets for the development of safer and more efficacious treatments.
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